What the FDA labels say about taking them together
Famotidine/ibuprofen and nilotinib
Famotidine/ibuprofen's FDA label of July 3, 2025 names nilotinib in its drug interactions section; the nilotinib labels PlainMeds reads (4) do not name famotidine/ibuprofen. The famotidine/ibuprofen label: “Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs.”
Check it at the source: the famotidine/ibuprofen FDA label on DailyMed (effective July 3, 2025, Aurobindo Pharma Limited); the nilotinib FDA label on DailyMed (effective December 16, 2025, Novartis Pharmaceuticals Corporation).
What does the famotidine/ibuprofen label say about nilotinib?
Famotidine/ibuprofen label, drug interactionsDrugs Dependent on Gastric pH for Absorption Clinical Impact: Because famotidine lowers intra-gastric acidity, this may result in reduced absorption and loss of efficacy of concomitant drugs. … gastric pH, refer to their prescribing information (e.g., atazanavir, erlotinib, ketoconazole, itraconazole, nilotinib, ledipasvir/sofosbuvir, and rilpivirine).
Source: FDA drug label (Ibuprofen and famotidine), Aurobindo Pharma Limited, effective July 3, 2025 (SPL set 21688404-41fb-487e-8ba0-aea4431a42fa), via openFDA; the full label on DailyMed
What does the nilotinib label say about famotidine/ibuprofen?
Nilotinib's label (effective December 16, 2025) and its 3 other brand-application labels do not name famotidine/ibuprofen in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tasigna), Novartis Pharmaceuticals Corporation, effective December 16, 2025 (SPL set 6093952a-5248-45cb-ad17-33716a411146), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Famotidine/ibuprofen | Nilotinib | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis | Leukemia, lymphoma and myeloma |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.714 per unit 800-26.6 mg | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once